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Members of the PPARγ coactivator-1 (PGC-1) family of transcriptional coactivators serve as inducible coregulators
of nuclear receptors in the control of cellular energy metabolic pathways. This Review focuses on the biologic and
physiologic functions of the PGC-1 coactivators, with particular emphasis on striated muscle, liver, and other organ
systems relevant to common diseases such as diabetes and heart failure.
Members of the nuclear receptor (NR) superfamily relay physiologic and nutritional cues to critical gene regulatory responses.
The molecular links between external stimuli, cellular signaling
events, and NR-mediated transcriptional control are currently
being unraveled. New information emerging over the past decade
has demonstrated that NRs receive regulatory input through multiple mechanisms including levels of endogenous ligand, availability
of heterodimeric NR partners, and posttranslational modifications.
Activating signals trigger the recruitment of coactivator complexes
onto the NR platform, leading to enzymatic modification of chromatin, increased access of the RNA polymerase II machinery to RNA,
and activation of target gene transcription (Figure 1). Availability of
certain coactivator proteins also serves critical regulatory functions
linking physiologic stimuli to NR activity. Perhaps the best example
of this latter mechanism involves the PPARγ coactivator-1 (PGC-1)
family of transcriptional coactivators. PGC-1 coactivators serve as
inducible NR “boosters” to equip the organism to meet the energy
demands of diverse physiologic and dietary conditions. This Review
will focus on the role of this interesting coactivator family in the
control of organ-specific biologic responses to the physiologic and
pathophysiologic milieu. Emphasis will be given to tissue-specific
regulatory features relevant to heart failure and diabetes.
5IF1($GBNJMZJOEVDJCMFUSBOTDSJQUJPOBMDPBDUJWBUPST
PSDIFTUSBUJOHDPOUSPMPGDFMMVMBSFOFSHZNFUBCPMJTN
The transcriptional coactivator PGC-1α was identified through its
functional interaction with the nuclear receptor PPARγ in brown
adipose tissue (BAT), a mitochondria-rich tissue specialized for
thermogenesis (1). Thereafter, 2 related coactivators, PGC-1β
(also termed PERC) and PGC-1–related coactivator (PRC), were
discovered (Figure 1) (2–4). PGC-1α and PGC-1β are preferentially
expressed in tissues with high oxidative capacity, such as heart,
slow-twitch skeletal muscle, and BAT, where they serve critical
roles in the regulation of mitochondrial functional capacity and
cellular energy metabolism (1, 3, 5–7). Less is known about the
expression patterns and biologic roles of PRC (2, 8).
Nonstandard abbreviations used: AMPK, AMP-activated protein kinase; BAT,
brown adipose tissue; CaMK, calcium/calmodulin–dependent protein kinase; ERR,
estrogen-related receptor; FOXO1, forkhead box O1; GLUT4, glucose transporter 4;
HNF-4, hepatic nuclear factor-4; MEF-2, myocyte enhancer factor-2; NR, nuclear
receptor; NRF, nuclear respiratory factor; PGC-1, PPARγ coactivator-1; PRC,
PGC-1–related coactivator; RNAi, RNA interference.
Conflict of interest: The authors have declared that no conflict of interest exists.
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PGC-1 coactivator docking to specific transcription factors provides a platform for the recruitment of regulatory protein complexes that exert powerful effects on gene transcription (Figure
1). The amino-terminal region of PGC-1 coactivators interacts
with proteins containing histone acetyltransferase (HAT) activity,
including CREB-binding protein/p300 and steroid receptor coactivator-1 (SRC-1) (9). The HAT activity of this complex remodels
histones within chromatin, increasing access of the transcriptional
machinery to target genes. A second activating complex, the thyroid hormone receptor–associated protein/vitamin D receptor–
interacting protein (TRAP/DRIP, or Mediator) complex, docks
on the carboxy terminus of PGC-1α (10). In addition, PGC-1α
contains several domains within the carboxy-terminal region that
couple pre-mRNA splicing with transcription (11).
Earlier studies involving forced overexpression of PGC-1α or
PGC-1β in mammalian cells in culture demonstrated that these
coactivators are sufficient to activate gene regulatory programs
that drive increased capacity for cellular energy production (3,
5, 7, 12). PGC-1 coactivators effect biologic responses that equip
the cell to meet the energy demands of a changing environment,
including augmentation of mitochondrial biogenesis, cellular
respiration rates, and energy substrate uptake and utilization.
The PGC-1 coactivators exert these pleiotropic effects by directly coactivating a specific array of NR and non-NR transcription
factors involved in the control of cellular metabolism. Following
its discovery as a PPARγ coactivator, Wu et al. demonstrated that
PGC-1α coactivates nuclear respiratory factor-1 (NRF-1) and -2
(NRF-2) (5). NRFs regulate expression of mitochondrial transcription factor A (Tfam), a nuclear-encoded transcription factor essential for replication, maintenance, and transcription of mitochondrial DNA (13–15). NRF-1 and NRF-2 also control the expression
of nuclear genes encoding respiratory chain subunits and other
proteins required for mitochondrial function (16, 17). These discoveries provided mechanistic insight into how PGC-1α activates
the broad program of mitochondrial biogenesis and revealed that
PGC-1 coactivators were capable of interacting with both NR and
non-NR transcription factors.
Although PPARγ, NRF-1, and NRF-2 are key targets of PGC-1α–
mediated coactivation, the diverse effects of this coactivator could
not be explained by these interactions alone. Multiple PGC-1α
partners have now been identified, indicating that this coactivator
serves as a pleiotropic regulator of multiple pathways involved in
cellular energy metabolism within and outside of the mitochondrion (Figure 2) (18, 19). Since the identification of PPARγ as a
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PGC-1α transcription factor target, a variety of additional PGC-1
target NRs have been identified. This list includes PPARα (20),
PPARβ (21), thyroid hormone receptor (1), retinoid receptors (1),
glucocorticoid receptor (22), estrogen receptor (1, 22, 23), farnesyl X receptor (FXR) (24), pregnane X receptor (PXR) (25), hepatic
nuclear factor-4 (HNF-4) (26), liver X receptor (LXR) (27), and the
estrogen-related receptors (ERRs) (28, 29). In addition, several
non-NR PGC-1 partners have been identified, including myocyte
enhancer factor-2 (MEF-2) (30), forkhead box O1 (FOXO1) (31),
SREBP1 (27), and Sry-related HMG box-9 (Sox9) (32). Through
these transcription factor partners, PGC-1 exerts strong effects on
many aspects of mitochondrial energy metabolism. For example,
PGC-1α coactivates PPARα, a key regulator of genes involved in
mitochondrial fatty acid oxidation (20). The PGC-1 target ERRα
is an important regulator of mitochondrial energy transduction
pathways including fatty acid oxidation and oxidative phosphorylation. In addition, ERRα is capable of cooperating with or directly
activating the expression of NRF-1, NRF-2, and PPARα, defining
an ERR “cross-regulatory circuit” that theoretically serves as an
internal “amplifier” for the PGC-1α cascade (Figure 2). Finally, several of the PGC-1 coactivation targets regulate pathways outside
of the mitochondrion — such as HNF-4 and FOXO1 (gluconeogenesis), MEF-2 (glucose transport), SREBP1 (lipogenesis), and
Sox9 (chondrogenesis). In addition to serving a booster function,
there is evidence that PGC-1 coactivators also confer target gene
specificity. For example, selective activation of PPARγ target genes
encoding aP2, uncoupling protein-1, and glycerol kinase is dictated, in part, by the PGC-1α/PPARγ interaction on these promoters
(1, 33). The mechanisms involved in the selection of specific targets by PGC-1α among tissues in a given physiologic context are
an important area of investigation.
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The discovery of PGC-1α as a cold-inducible coactivator
prompted studies to determine whether its expression is regulated
by developmental, physiologic, and dietary cues. One of the first
clues that PGC-1α and PGC-1β serve diverse functions in multiple organ systems was the observation that they are expressed
in broad, but tissue-enriched, patterns. PGC-1α and PGC-1β are
highly expressed in mitochondria-enriched tissues with high energy demands, including BAT, heart, and slow-twitch skeletal muscle (1, 3, 4). PGC-1α is also enriched in brain and kidney. PGC-1α
expression is induced in the heart after birth in parallel with a postnatal burst of mitochondrial biogenesis and a shift toward reliance
on mitochondrial fatty acid oxidation as the major source of ATP
production (12). The PGC1A gene is highly inducible in response
to physiologic conditions that demand increased mitochondrial
energy production. For example, PGC-1α expression is stimulated
by exercise in skeletal muscle (34–38) and by fasting in the heart
and liver (12, 26). Interestingly, PGC-1β expression is also induced
by fasting, but not cold exposure, indicating that factor-specific
upstream regulatory circuits exist (3, 39).
As would be predicted by its inducibility, the expression and
activity of PGC-1α are linked to a variety of upstream cellular signaling pathways (Figure 2). In BAT and liver (and likely other tissues), the β-adrenergic/cAMP pathway activates PGC1A gene transcription (1). Calcineurin A and calcium/calmodulin–dependent
protein kinase (CaMK) activate PGC-1α expression in striated
muscle (40–42). The AMP-activated protein kinase (AMPK) has
also been implicated in the control of muscle PGC-1α expression
(43). p38 MAPK has been shown to activate PGC-1α by releasing
p160-mediated repression and by increasing PGC-1α protein stability (44–46). More recently, NO was shown to activate mitochondrial biogenesis coincident with increased PGC-1α expression in
a variety of cell types, including adipocytes and HeLa cells (47).
Given the known role of NO as a vasodilator, it is tempting to
speculate that this key upstream regulatory pathway coordinately
regulates downstream events including an increase in the capacity to utilize oxygen in mitochondria. In addition to phosphorylation, other posttranslational modifications, including acetylation,
arginine methylation, and interaction with repressor proteins (e.g.,
p160), modulate PGC-1α activity (45, 48, 49).
The transcriptional regulatory factors that link upstream signaling pathways to PGC1A gene expression are being delineated.
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The calcineurin A–mediated activation of the PGC1A promoter is
dependent on MEF-2 response elements, whereas CaMK-mediated
regulation requires CREB-binding sites (40–42). The transcription
factor CREB activates PGC1A gene transcription in hepatocytes,
implicating this factor in the PGC-1α–mediated control of gluconeogenesis (50). The forkhead transcription factor FOXO1 activates the human PGC1A promoter in a hepatoma cell line (51), an
effect that is suppressed by protein kinase B/Akt signaling, suggesting a mechanism for negative regulation of PGC-1α expression by insulin in the liver.
Given that PGC-1α integrates regulatory input from a variety
of upstream regulatory pathways among multiple tissues, in vivo
studies have been necessary to define the bona fide biologic functions downstream of this powerful transcriptional coactivator. In
vivo studies have been empowered by the development of generalized and conditional transgenic PGC-1α gain-of-function mouse
models. In addition, 2 independent generalized PGC-1α–deficient
mouse lines (Pgc1a–/– mice) have been generated using gene targeting strategies (52, 53). Both lines are viable and exhibit multisystem energy metabolic abnormalities that were unveiled by physiologic or nutritional stressors.

1($TJHOBMJOHBOEUIFIFBSU
The extraordinary energy demands of the heart are met by a highcapacity mitochondrial system. Accordingly, it is not surprising
that PGC-1α and PGC-1β are highly expressed in this organ (1, 3,
54). Although the exact roles of PGC-1β and PRC in heart have not
been defined, several lines of evidence indicate that PGC-1α controls cardiac energy metabolic pathways during development and in
response to physiologic stressors. First, cardiac PGC-1α expression
is induced after birth as the heart turns toward mitochondrial fatty
acid oxidation as the chief energy source (12). PGC-1α expression is
also activated in the heart by fasting (12), a physiologic stimulus that
markedly increases the reliance of the heart on mitochondrial fat
oxidation for ATP production. Second, PGC-1α coactivates PPARα
and ERRα, NRs that control genes involved in cardiac fatty acid oxidation and mitochondrial respiratory function (55). Third, forced
overexpression of PGC-1α in cardiac myocytes in culture activates
mitochondrial biogenesis (12). Interestingly, in contrast to the BAT,
where PGC-1α drives uncoupled respiration, PGC-1α overexpression
drives coupled respiration in the cardiac myocyte (12).
Gain-of-function studies in transgenic mice have demonstrated
potential biologic functions of PGC-1α in the heart in vivo. Two
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transgenic mouse models with cardiac-restricted overexpression
of PGC-1α have been developed. In the first model, mice with
constitutive, postnatal cardiac overexpression of PGC-1α under
control of the cardiac α-myosin heavy chain promoter (MHC–
PGC-1α mice) were generated (12). The hearts of MHC–PGC-1α
mice exhibit marked activation of cardiac myocyte mitochondrial
biogenesis, leading, ultimately, to death from heart failure (12).
Subsequently, a bitransgenic, tissue-specific, tetracycline-inducible PGC-1α mouse was established (the cs-tet-on PGC-1α mouse)
(56). Studies of cs-tet-on PGC-1α mice revealed developmental
stage-specific effects of PGC-1α. Overexpression of PGC-1α in
neonatal heart triggers dramatic expansion of mitochondria within the cardiac myocytes. In contrast, acute cardiac overexpression
of PGC-1α in adult mice results in a modest mitochondrial biogenic response and, after several weeks, cardiomyopathy associated with mitochondrial ultrastructural abnormalities. The basis
for cardiomyopathy following PGC-1α activation is unknown but
likely involves dysregulated mitochondrial metabolism.
Recent loss-of-function studies further support a role for
PGC-1α in the control of myocardial metabolism and function. Interestingly, the severity of the cardiac phenotype varies
between the 2 independently generated lines of PGC-1β–deficient mice. Both lines demonstrate that PGC-1α is not essential
for the fundamental process of mitochondrial biogenesis in the
heart; myocardial mitochondrial volume density is not significantly altered in either Pgc1a–/– line (53, 57). The PGC-1α–deficient mice produced by the Spiegelman group exhibit moderate, age-related base-line cardiac dysfunction as determined by
echocardiography (57). Hearts isolated from this line of mice
also exhibit a modest impairment in maintenance of ATP and
phosphocreatine homeostasis in response to the β-adrenergic
agonist dobutamine as determined by NMR spectroscopy. These
metabolic abnormalities are associated with diminished expression of genes involved in mitochondrial fatty acid oxidation,
the TCA cycle, and oxidative phosphorylation. In contrast, the
PGC-1α–deficient mice produced by Leone et al. do not exhibit
overt dysfunction by echocardiography under basal conditions;
however, this second line of Pgc1a–/– mice exhibit a blunted heart
rate response to exercise and β-adrenergic stimulation (53). The
mechanistic basis for the dissimilarities between the 2 lines of
Pgc1a–/– mice is unclear. It is possible that epigenetic effects due
to differences in strain background or gene targeting strategies
account for the divergent phenotypes.
Several lines of recent evidence implicate PGC-1α in the pathogenesis of heart failure. First, in mouse models of chronic pressure
overload such as occurs in long-standing hypertension, PGC-1α
levels are downregulated along with the expression of PPARα target genes involved in mitochondrial fatty acid oxidation (58–60).
Second, transcriptional profiling revealed downregulation of
PGC-1α gene expression in the failing hearts of transgenic mice in
which cyclin T/Cdk9, an RNA polymerase kinase, is overexpressed
in the heart (61, 62). Forced expression of PGC-1α in the mutant
cardiac myocytes prevented the apoptotic phenotype (62). These
results are interesting given that mitochondrial respiratory function and high-energy phosphate stores are known to be reduced
in end-stage heart failure (63). Lastly, chronic overexpression of
PGC-1α in heart leads to a cardiomyopathic phenotype (12, 56).
Thus, emerging evidence links altered PGC-1α activity to cardiac
dysfunction. However, whether PGC-1α plays an etiologic role in
the pathogenesis of heart failure remains to be determined.
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The expression of PGC-1α is enriched in skeletal muscle, particularly in oxidative fiber types. Studies in rodent models indicate that
both short-term exercise and endurance training activate PGC-1α
expression in skeletal muscle (34, 35, 64, 65). Subsequent studies
in humans have further demonstrated remarkable inducibility of
PGC-1α in response to acute bouts of exercise or endurance training (38, 66) and have indicated that PGC-1α levels are increased
mainly in type IIa fibers after endurance training (66). Although
the upstream signaling events involved in the activation of PGC-1α
expression in exercising muscle are not well defined, several pathways have been implicated. The calcineurin A and CaMK pathways
are linked to muscle PGC1A gene transcription through MEF-2
factors (40–42). Recently, the p38 MAPK and AMPK pathways
have also been implicated in the control of PGC-1α expression in
skeletal muscle after exercise training (43, 67).
The biologic roles of PGC-1α in skeletal muscle have been elucidated largely through murine gain-of-function and loss-of-function studies. Lin et al. developed mice with skeletal muscle–specific overexpression of PGC-1α driven by the muscle creatine
kinase (MCK) promoter (68). Forced expression of PGC-1α at
high physiologic levels in the MCK transgenic mice resulted in an
increased proportion of oxidative or type I muscle fibers coincident with an increase in the expression of mitochondrial markers.
This fiber type transition was also manifest by red muscle coloration, increased expression of contractile protein characteristic of
type I fibers, and resistance to electrically stimulated fatigue (68).
These results indicated that PGC-1α is sufficient to drive the slowtwitch skeletal muscle program. Complementary loss-of-function
studies demonstrated that Pgc1a–/– mice exhibit diminished mitochondrial number and respiratory capacity in slow-twitch skeletal
muscle (53). In contrast, measures of mitochondrial function and
density are normal in fast-twitch fibers of the PGC-1α–deficient
mice. However, exercise capacity, as measured on a motorized
treadmill, and fatigue resistance index in electrically stimulated
muscle, are significantly reduced in the Pgc1a–/– mice (53). Taken
together, these results strongly implicate PGC-1α signaling as a
key mediator of the energy metabolic and structural adaptation
of muscle to exercise.
Recent evidence also implicates PGC-1α in the regulation of
muscle glucose metabolism. The first clue came from studies demonstrating that PGC-1α robustly activates expression of glucose
transporter 4 (GLUT4) in skeletal muscle cells in culture by coactivating MEF-2c (30). More recently, PGC-1α was found to repress
glucose oxidation in muscle cell lines by activating the expression
of the gene encoding pyruvate dehydrogenase kinase 4 via its NR
partner, ERRα (69). These latter results suggest that PGC-1α controls muscle fuel selection by increasing fatty acid oxidation while
temporarily shutting down glucose oxidation — a gene regulatory
equivalent of the fatty acid–glucose cycle. Inhibition of glucose
oxidation combined with increased muscle glucose uptake could
serve to replenish muscle glycogen stores to prepare for the next
bout of exercise.
1($TJHOBMJOHBOEIFQBUJDGVODUJPO
Under normal, ad libitum–fed conditions, the expression of
PGC-1α and PGC-1β is relatively low in liver compared with
other tissues that rely on aerobic metabolism for ATP production
(1, 39). However, hepatic PGC1A and PGC1B gene expression is
robustly induced by fasting (39, 50, 70). During short-term star-
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vation, the fatty acid oxidation pathway is a key source of substrates for ATP production, ketogenesis, and gluconeogenesis.
PGC-1α and PGC-1β activate expression of PPARα target genes
involved in hepatic fatty acid oxidation (39, 70, 71), and acute
RNA interference–mediated (RNAi-mediated) PGC-1α knock
down leads to profound downregulation of fatty acid oxidation
gene expression (71). Rates of fatty acid oxidation are also diminished in hepatocytes isolated from PGC-1α–deficient mice (53).
The reduction in fatty acid oxidative capacity likely contributes to
the fasting-induced hepatic steatotic phenotype observed in one
of the mutant lines (53). Surprisingly, the expression of PPARα
target genes involved in β-oxidation is not reduced in generalized Pgc1a–/– mice (52, 53). However, hepatocytes isolated from
PGC-1α–deficient mice exhibit diminished mitochondrial respiration rates (53), providing one mechanistic explanation for the
reduced capacity for hepatic fatty acid oxidation.
During periods of fasting, the liver catabolizes fatty acids to produce 3-carbon substrates for gluconeogenesis, the most important source of de novo glucose production in higher organisms.
PGC1A gene expression is activated in liver by fasting (50, 70)
and glucocorticoids (72), and it is now recognized that it regulates hepatic gluconeogenesis (31, 50, 70, 71). Ectopic expression
of PGC-1α coactivates HNF-4α and FOXO1 to drive expression
of genes involved in gluconeogenesis (31), whereas PGC-1β does
not activate this pathway (39). The nutrient sensor SIRT1, which
is linked to longevity in several animal models, also exerts critical posttranslational regulatory control of gluconeogenic gene
expression via deacetylation of PGC-1α (48). Liver-specific PGC1A
gene deletion studies (73) and acute RNAi-based PGC-1α hepatic
knockdown strategies (71) in mice lead to diminished expression of genes encoding gluconeogenic enzymes. After short-term
starvation, one of the lines of generalized Pgc1a–/– mice becomes
hypoglycemic (52), consistent with a defect in the hepatic gluconeogenic response. However, the basal expression of key gluconeogenic genes such as PEPCK is either normal (53) or increased (52)
in the PGC-1α–deficient lines. Accordingly, it is not clear whether
the major regulatory effect of PGC-1α on this pathway occurs via
direct transcriptional control of gluconeogenic genes or secondarily to reductions in flux through fatty acid oxidation or the TCA
cycle, which are coupled to, and required for, gluconeogenesis.

A striking example of gene target selectivity between PGC-1α
and PGC-1β was recently unveiled in liver. Administration of a
diet enriched in saturated or trans-fatty acids resulted in acute
induction of hepatic PGC-1β expression without altering PGC-1α
expression (27). PGC-1β overexpression in liver stimulated hepatic triglyceride production and secretion, resulting in circulating
hypertriglyceridemia and hypercholesterolemia. Conversely, it
was previously shown that activation of PGC-1α in liver diminished triglyceride production and secretion (24). The mechanistic
explanation for these surprising results came from gene regulatory
studies demonstrating that PGC-1β, but not PGC-1α, activates the
expression of genes involved in lipogenesis and triglyceride secretion via direct coactivation of SREBP1c (27), a transcription factor
that plays a critical role in the control of lipogenesis. The region of
PGC-1β that mediates the protein-protein interaction with SREBP
is not conserved among PGC-1 family members; this provides an
explanation for the observed isoform selectivity. This work provides a potential mechanistic basis for the known association
between diets high in saturated or trans-fat and hyperlipidemia.
In sum, evidence is mounting that induction of PGC-1α and
PGC-1β expression in liver is a critical regulatory event leading to
the activation of energy metabolic pathways that serve to increase
ATP production and exert homeostatic control, especially in the
context of fasting. Given the importance of hepatic lipid metabolic
derangements in common diseases such as nonalcoholic steatotic
hepatitis and alcoholic liver disease, as well as the link between liver
insulin resistance and diabetes, the PGC-1 regulatory circuits represent potential new therapeutic targets for hepatic disease states.
1BSBEPYJDBMSPMFTGPS1($αJOJOTVMJOSFTJTUBODF
BOEEJBCFUFTNFMMJUVT
Recent studies in animal models and in humans link altered PGC-1α
signaling to glucose intolerance, insulin resistance, and diabetes.
However, the role of PGC-1α as a protective factor versus mediator of disease progression is unclear, particularly given that its
predicted effects on insulin sensitivity and glucose tolerance vary
across tissues (Figure 3). Associations between PGC-1α and diabetes have been identified in studies of human genetic variants. A
common polymorphism in the coding region of the PGC1A gene
(Gly482Ser) and a specific promoter haplotype are associated with
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an increased risk of type 2 diabetes (74–81). However, other studies have not found this association (82, 83). Additionally, the target tissues affected and whether these polymorphisms result in
increased or decreased PGC-1α activity remain unclear.
PGC-1α activity is robustly activated in diabetic liver as it is in
the fasted state (26, 31, 50, 70), potentially increasing hepatic glucose production that contributes to circulating hyperglycemia.
Moreover, PGC-1α may promote insulin resistance directly by
inducing TRB-3, an inhibitor of Akt signaling, a critical downstream component of the insulin signaling pathway (71). The
precise mechanisms involved in the regulatory cross-talk between
insulin signaling and PGC-1α activity in the diabetic state represent an area of active research.
In the pancreatic β cell, rates of mitochondrial ATP synthesis are
inexorably coupled to insulin secretion by ATP-sensing K+ channels, which control insulin release. PGC-1α is also activated in the β
cell in several rodent models of obesity and type 2 diabetes (84), and
PGC-1α overexpression suppressed glucose-stimulated membrane
depolarization and insulin secretion in cultured islets or insulinoma cell lines (84). Moreover, whereas transplantation of normal
islets into mice rendered diabetic by streptozotocin returned blood
glucose levels to normal, PGC-1α–overexpressing islets were unable
to reverse experimentally induced diabetes. The β cell phenotype of
the PGC-1α–deficient mice and the effects of other PGC-1 family
members in the β cell have not yet been delineated.
In contrast to results in liver and the β cell, the bulk of evidence focused on skeletal muscle suggests that PGC-1α may be
protective from the development of insulin resistance. First, as
described above, PGC-1α activates expression of GLUT4 (30).
Second, PGC-1β overexpression in skeletal muscle protects
mice from high-fat diet–induced obesity and insulin resistance
(6). Third, inherited mitochondrial deficiencies are linked with
the development of systemic metabolic defects and diabetes
(85). Accordingly, PGC-1α, a critical booster of mitochondrial
function, is an excellent candidate for preventing insulin resistance secondary to mitochondrial dysfunction. Fourth, a series
of recent studies in humans have shown an interesting inverse
correlation between muscle PGC-1α levels and mitochondrial
activity with insulin resistance and diabetes (86–88). However, a
separate recent study did not find a correlation between muscle
mitochondrial derangements and PGC-1α levels in insulin-resistant humans (89). Given that the published results focused on
PGC-1α levels in insulin-resistant muscle are largely correlative,
the role of alterations in PGC-1α activity as etiologic versus a
secondary phenomenon remains unclear.
One approach to unraveling the paradoxical, tissue-specific
actions of PGC-1α on systemic glucose metabolism and insulin
sensitivity is through studies of recently developed genetically
modified mouse models. Systemic glucose tolerance and insulin
sensitivity have been characterized in both PGC-1α–deficient lines.
Although some differences exist in the 2 lines, the results indicate
1. Puigserver, P., et al. 1998. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 92:829–839.
2. Andersson, U., and Scarpulla, R.C. 2001. PGC-1related coactivator, a novel, serum-inducible coactivator of nuclear respiratory factor-1-dependent
transcription in mammalian cells. Mol. Cell. Biol.
21:3738–3749.
3. Lin, J., Puigserver, P., Donovan, J., Tarr, P., and Spiegelman, B.M. 2002. Peroxisome proliferator-acti

that both Pgc1a–/– lines are modestly protected against insulin
resistance caused by high-fat diet. Interestingly, this insulin-sensitive phenotype occurs despite reduced respiratory capacity of
mitochondria in the skeletal muscle of the mice (53). It is possible that reduced hepatic glucose production via the gluconeogenic pathway contributes to the enhanced glucose tolerance of
PGC-1α–deficient mice (Figure 3). Indeed, as described above,
liver-specific overexpression and knockdown strategies indicate
that PGC-1α, when activated, drives hepatic glucose production,
a potential contributor to the development of obesity-related diabetes. In addition, one of the PGC-1α–deficient lines exhibited
increased activity and partial resistance to weight gain, which
could contribute to the phenotype (52). Given the mounting evidence of a link between diabetes and PGC-1α activity, this represents an important focus for future investigation.
1($DPBDUJWBUPSTUIFGVUVSF
A recent explosion of new information indicates that the PGC-1
family of coactivators serves key functions in the dynamic transcriptional control of energy metabolic pathways in a variety of
mammalian tissues. The importance of PGC-1α and PGC-1β as
boosters of NR function has provided exciting new avenues for
understanding the fundamental connections between alterations
in the external environment and adaptive metabolic responses of
striated muscle and liver. Moreover, evidence is mounting that
dysregulation of the PGC-1α regulatory axis contributes to the
pathogenesis of common disease states including diabetes and
heart failure. However, the role of these powerful and highly inducible coactivators as protectors versus mediators of disease has not
been well defined and will require additional translational studies
bridging animal models, such as conditional genetically modified
mouse models, and humans. Given the versatile and pleiotropic
nature of the PGC-1 family regulatory circuit, it is envisioned that,
after the elucidation of the precise roles of these coactivators in
disease states, specific PGC-1/NR regulatory limbs could prove to
be exciting new therapeutic targets.
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